Clinical trial · Interventional
Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial
Compression Therapy as a Prophylactic Method Against Paclitaxel-induced Peripheral Neuropathy: a Prospective Self-controlled Trial
NCT05531916CI-TRIAL-00110000CIPNactive not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single-center, self-controlled, evaluator-blinded prospective study, which applies pressurized gloves and foot caps to prevent paclitaxel-induced peripheral neuropathy in patients with nasopharyngeal carcinoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CIPN - Chemotherapy-Induced Peripheral Neuropathy | — | UNRESOLVED | — |
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pressurized gloves and foot caps | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group A
- description
- Participants wear pressurized gloves and foot caps for 15 minutes before their chemotherapy treatment, during the treatment, and for 15 minutes after it ended.
- interventionNames
- Other: Pressurized gloves and foot caps
- type
- NO_INTERVENTION
- label
- Group B
- description
- No intervention was done before and after chemotherapy with paclitaxels.
Primary outcomes (1)
- measure
- Evaluation change in CTCAE 5.0 grade for CIPN (The most severe grade is the final grade)
- timeFrame
- Pretreatment (baseline=0), just after 15 minutes of each treatment cycle (each cycle of chemotherapy is 21 days) , 3 and 6 months after chemotherapy completion.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age range from 18 to 70 * ECOG physical status score: 0-2 * Newly diagnosed patients who have not received antitumor therapy * Nasopharyngeal carcinoma confirmed by pathology * Paclitaxel is included in the chemotherapy regimen * Laboratory examination results within one week before enrollment should meet the following conditions: neutrophils (ANC) ≥1.5×109/L, platelets (PLT) ≥80×109/L, total bilirubin (TBI) ≤1.5× upper limit of normal value (2mg/ dL), ALT and AST ≤2× upper limit of normal value * Patients voluntarily participate and provide written informed consent Exclusion Criteria: * Patients with peripheral neuropathy, hand-foot syndrome, and dermatomyositis * Patients with missing fingers or toes * Patients with Raynaud's syndrome and peripheral vascular ischemia * Pregnant or lactating women * Those considered unsuitable for inclusion by the researcher
References
Publications (0)
Data not yet available
No reference posted for this study.